Robert Chess, Director at NEKTAR THERAPEUTICS (NKTR), sold 4,600 shares at $17.94 ($83K) on 2021-09-22, disclosed to the SEC on 2021-09-24.
Seasonal sale ($83k) by Director — this insider has traded NKTR in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| TWST | SELL | 2026-02-18 | $105K | — | Filing → |
| TWST | SELL | 2025-02-11 | $312K | — | Filing → |
| TWST | SELL | 2025-01-10 | $250K | — | Filing → |